Evidence map›Paper›PMID 28768533›Full record

ArticleJournal of neuroinflammation2017

Progression of pathology in PINK1-deficient mouse brain from splicing via ubiquitination, ER stress, and mitophagy changes to neuroinflammation.

Sylvia Torres-Odio, Jana Key, Hans-Hermann Hoepken, Júlia Canet-Pons, Lucie Valek, Bastian Roller, Michael Walter, Blas Morales-Gordo, David Meierhofer, Patrick N Harter and 4 more

Open access · goldAbstract read
In one paragraph

Article in Journal of neuroinflammation, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 56 papers.

0numbers the graph read from it
0cells of the map it votes in
56citing papers in PubMed
7.2field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

56 citing papers in PubMed, 90 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Review
  14. Review
  15. Article
  16. Article
  17. Review
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 5 institutions in 3 countries.

Sylvia Torres-OdioExperimental Neurology, Goethe University Medical School, 60590, Frankfurt am Main, Germany.
Jana KeyExperimental Neurology, Goethe University Medical School, 60590, Frankfurt am Main, Germany.
Hans-Hermann HoepkenExperimental Neurology, Goethe University Medical School, 60590, Frankfurt am Main, Germany.
Júlia Canet-PonsExperimental Neurology, Goethe University Medical School, 60590, Frankfurt am Main, Germany.
Lucie ValekInstitute of Clinical Pharmacology, Goethe University Medical School, 60590, Frankfurt am Main, Germany.
Bastian RollerEdinger-Institute (Institute of Neurology), Goethe University Medical School, 60590, Frankfurt am Main, Germany.
Michael WalterInstitute for Medical Genetics, Eberhard-Karls-University of Tuebingen, 72076, Tuebingen, Germany.
Blas Morales-GordoDepartment of Neurology, University Hospital San Cecilio, 18012, Granada, Spain.
David MeierhoferMax Planck Institute for Molecular Genetics, Ihnestraße 63-73, 14195, Berlin, Germany.
Patrick N HarterEdinger-Institute (Institute of Neurology), Goethe University Medical School, 60590, Frankfurt am Main, Germany.
Michel MittelbronnEdinger-Institute (Institute of Neurology), Goethe University Medical School, 60590, Frankfurt am Main, Germany.
Irmgard TegederInstitute of Clinical Pharmacology, Goethe University Medical School, 60590, Frankfurt am Main, Germany.
Suzana GispertExperimental Neurology, Goethe University Medical School, 60590, Frankfurt am Main, Germany.
Georg AuburgerExperimental Neurology, Goethe University Medical School, 60590, Frankfurt am Main, Germany. auburger@em.uni-frankfurt.de.
Goethe University Frankfurt · DEInstituto de Investigación Biosanitaria de Granada · ESLuxembourg Institute of Health · LUMax Planck Institute for Molecular Genetics · DEUniversity of Tübingen · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPINK1 deficiency causes the autosomal recessive PARK6 variant of Parkinson's disease. PINK1 activates ubiquitin by phosphorylation and cooperates with the downstream ubiquitin ligase PARKIN, to exert quality control and control autophagic degradation of mitochondria and of misfolded proteins in all cell types.

methodsGlobal transcriptome profiling of mouse brain and neuron cultures were assessed in protein-protein interaction diagrams and by pathway enrichment algorithms. Validation by quantitative reverse transcriptase polymerase chain reaction and immunoblots was performed, including human neuroblastoma cells and patient primary skin fibroblasts.

resultsIn a first approach, we documented Pink1-deleted mice across the lifespan regarding brain mRNAs. The expression changes were always subtle, consistently affecting "intracellular membrane-bounded organelles". Significant anomalies involved about 250 factors at age 6 weeks, 1300 at 6 months, and more than 3500 at age 18 months in the cerebellar tissue, including Srsf10, Ube3a, Mapk8, Creb3, and Nfkbia. Initially, mildly significant pathway enrichment for the spliceosome was apparent. Later, highly significant networks of ubiquitin-mediated proteolysis and endoplasmic reticulum protein processing occurred. Finally, an enrichment of neuroinflammation factors appeared, together with profiles of bacterial invasion and MAPK signaling changes-while mitophagy had minor significance. Immunohistochemistry showed pronounced cellular response of Iba1-positive microglia and GFAP-positive astrocytes; brain lipidomics observed increases of ceramides as neuroinflammatory signs at old age. In a second approach, we assessed PINK1 deficiency in the presence of a stressor. Marked dysregulations of microbial defense factors Ifit3 and Rsad2 were consistently observed upon five analyses: (1) Pink1

conclusionsThus, an individual biomarker with expression correlating to progression was not identified. Instead, more advanced disease stages involved additional pathways. Hence, our results identify PINK1 deficiency as an early modulator of innate immunity in neurons, which precedes late stages of neuroinflammation during alpha-synuclein spreading.

Indexed as

Age FactorsAgingalpha-SynucleinAnimalsCalcium-Binding ProteinsCells, CulturedCerebral CortexDisease Models, AnimalDisease ProgressionEndoplasmic Reticulum StressGene Expression ProfilingHumansLipid MetabolismMiceMice, TransgenicMicrofilament ProteinsAif1 protein, mousealpha-SynucleinCalcium-Binding ProteinsMicrofilament ProteinsProtein KinasesPTEN-Induced Putative KinaseAntiviral responseMitochondrial dysfunctionNeuroinflammationParkinson’s diseaseUbiquitin kinase PINK1

Identifiers

PMID28768533
PMCPMC5541666
OpenAlexW2739804116

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.